JAE KYO LEE
Medical Practice in San Diego, CA

6043386, Mar 28, 2000

Jun 1, 1999

9/323106

Gary H. Posner - Baltimore MD
Jae Kyoo Lee - San Diego CA
Qiang Wang - Baltimore MD

John Hopkins University - Baltimore MD

C07C40100, A61K 3159

552653

Fluorinated analogs of 1. alpha. ,25-dihydroxyvitamin D. sub. 3. These analogs are synthesized in a convergent manner by joining A-ring and C,D-ring fragments. Each hybrid analog, having a calcemia-lowering 1-hydroxymethyl group and a potentiating 16-ene-24,24-difluorinated C,D-ring and side chain, is designed to be lipophilic and inert toward 24-hydroxylase enzyme catabolism. Each hybrid analog with 1. beta. ,3. alpha. -substituent stereochemistry shows a pharmacologically desirable combination of high antiproliferative and high transcriptional activities in vitro and also low calcemic activity in vivo.

8266490, Sep 11, 2012

Apr 8, 2009

12/420654

Su-Lin Low - San Diego CA, US
Jae Sun Lee - San Diego CA, US

VIA Telecom, Inc. - San Diego CA

G06F 11/00

714749, 714748, 714746

A method for providing improved reverse link transmission timing in an access terminal is provided. The method includes processing automatic repeat request (ARQ) bits from a MAC bit processing unit for a previous sub-frame. The ARQ bits comprise a hybrid ARQ (H-ARQ) bit, a last ARQ (L-ARQ) bit, and a packet ARQ (P-ARQ) bit. The method also includes calculating the maximum allowed reverse rate and grant size for a MAC flow. The method further includes distributing grants to each application in the MAC flow. The method also includes storing a stored read pointer in an application transmit queue, for each application in the MAC flow. The method also includes preparing data for transmission, in response to storing the stored read pointer for each application in the MAC flow, based on the ARQ bits. The method also includes transmitting the data.

8228817, Jul 24, 2012

Apr 6, 2010

12/754684

Jae Sun Lee - San Diego CA, US
Su-Lin Low - San Diego CA, US

Via Telecom, Inc. - San Diego CA

H04L 12/26, G08C 25/02, H04W 24/00

370252, 714748, 455423

A mobile communication device for providing QoS of packet transmission is provided. The packet transmission from and to the mobile communication device is performed by repeating a predetermined number of interlaces by a predetermined cycle. In the mobile communication device, a wireless module transmits a first sub-packet of a first packet and a first sub-packet of a second packet to a mobile communication network, and receives a response message corresponding to the first sub-packet of the first packet from the mobile communication network, wherein the first sub-packet of the first packet is transmitted in a first interlace prior to a second interlace in which the first sub-packet of the second packet is transmitted. Also, a controller module calculates a plurality of QoS parameters for a second sub-packet of the second packet in response to the response message, prepares the second sub-packet of the second packet with the QoS parameters, and transmits the second sub-packet of the second packet in the second interlace to the mobile communication network via the wireless module.

8574635, Nov 5, 2013

Feb 16, 2011

12/932018

Sylvia Lee-Huang - New York NY, US
Paul L. Huang - Boston MA, US
Philip Lin Huang - Maple Glen PA, US
Dawei Zhang - Elmhurst NY, US
John Z. H. Zhang - New York NY, US
Young Tae Chang - New York NY, US
Jae Wook Lee - San Diego CA, US
Ju Bao - Brooklyn NY, US
Yongtao Sun - Xi'an, CN

New York University - New York NY
The General Hospital Corporation - Boston MA

A01N 65/00

424725

The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues.